Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) (344139)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save this grant

Next deadline: Aug 25, 2023 (Letter of inquiry)

Later deadlines: Sep 25, 2023 (Full proposal), Aug 25, 2024 (Letter of inquiry), Sep 25, 2024 (Full proposal), Aug 25, 2025 (Letter of inquiry), Sep 25, 2025 (Full proposal)

Grant amount: Up to US $1,500,000

Fields of work: Genetics & Genomics Addiction & Substance Use Disorders

Applicant type: Government Entity, Nonprofit, For-Profit Business, Indigenous Group

Funding uses: Research

Location of project: United States

Location of residency: United States


NOTE: All applications are due by 5:00 PM local time of applicant organization. 

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

Application budgets are limited to $300,000 in Direct Costs each year for up to five years, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed October 23, 2022 and last updated October 23, 2022